Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Usana Health Sciences, Inc. · 10-Q · Q2 FY2026 · Period ended Jul 4, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

We have no material changes to the disclosures on this matter made in our 2025 Form 10-K. For a discussion of our exposure to market risk, refer to our market risk disclosures set forth in the section entitled “Quantitative and Qualitative Disclosures About Market Risk” in the 2025 Form 10-K.